iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update

iTeos Therapeutics, Inc. (NASDAQ:ITOS) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,820,000 shares, an increase of 92.0% from the September 15th total of 2,510,000 shares. Based on an average daily volume of 518,700 shares, the days-to-cover ratio is presently 9.3 days. Currently, 17.2% of the shares of the company are sold short.

iTeos Therapeutics Stock Up 9.7 %

Shares of ITOS opened at $9.95 on Friday. The company has a 50-day moving average price of $13.84 and a two-hundred day moving average price of $14.47. The stock has a market cap of $363.37 million, a price-to-earnings ratio of -3.32 and a beta of 1.36. iTeos Therapeutics has a 12 month low of $8.20 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.86. The company had revenue of $35.00 million for the quarter, compared to the consensus estimate of $4.20 million. Equities research analysts expect that iTeos Therapeutics will post -3.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ITOS shares. Wells Fargo & Company assumed coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research report on Monday, September 16th.

Institutional Investors Weigh In On iTeos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ITOS. Acadian Asset Management LLC acquired a new position in shares of iTeos Therapeutics in the 1st quarter worth approximately $3,337,000. Clearline Capital LP acquired a new position in iTeos Therapeutics in the second quarter worth $2,328,000. Candriam S.C.A. bought a new stake in shares of iTeos Therapeutics during the second quarter worth $7,558,000. Kennedy Capital Management LLC bought a new stake in shares of iTeos Therapeutics during the first quarter worth $1,988,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after buying an additional 117,159 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.